HOOKIPA Pharma Inc
NASDAQ:HOOK
During the last 3 months HOOKIPA Pharma Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 15% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nasdaq/hook/vs/indx/gspc">open performance analysis).
The last transaction was made on
Aug 19, 2025
by
Peters Malte
, who
sold
20.7k USD
worth of
HOOK shares.
During the last 3 months HOOKIPA Pharma Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 15% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nasdaq/hook/vs/indx/gspc">open performance analysis).
The last transaction was made on
Aug 19, 2025
by
Peters Malte
, who
sold
20.7k USD
worth of
HOOK shares.
HOOKIPA Pharma Inc
Glance View
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. The company is headquartered in New York City, New York and currently employs 131 full-time employees. The company went IPO on 2019-04-18. The firm is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its pipeline candidates include HB-200, HB-300, HB-700, HB-101, HB-101 and HBV Therapy. The HB-200 program consists of its arenaviral-based immunotherapies for the treatment of patients with advanced/metastatic cancers caused by 16-positive (HPV16+). Its lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papillomavirus HPV16+ cancers in a Phase I/II clinical trial. Its non-replicating prophylactic Cytomegalovirus vaccine candidate, HB-101, is for patients awaiting kidney transplantation in Phase II clinical trial.
What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.